Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
- Bioconjugation capability complements commercial payload, linker and monoclonal antibodies services
- Expansion places Syngene among a handful of CDMOs with full-service capabilities
Syngene International is adding a GMP bioconjugation suite at its commercial biologics facility in Bengaluru.
Author's summary: Syngene International expands ADC development capabilities.
More News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Milestone weekend recognises legends
- Anglicans need more than one boat - THE OTHER CHEEK
- Lassus Handy Dandy gas stations now accepting donations on behalf of ‘Blessings in a Backpack’
- Action across the nation to ban greyhound racing
- First Duel Night Abyss Figure Is Based on Psyche
- Voters hand Milei belated birthday present, post-mortem for Peronism overdue
- Lightning place forward Mitchell Chaffee on waivers
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids